BackgroundMyotonic Dystrophy Type 1 (DM1) is a multisystem genetic disorder and the most common muscular dystrophy in adults. Central nervous system involvem...

Cardiac involvement occurs in approximately 80% of patients with myotonic dystrophy type 1 (DM1), and annual follow-up with a routine 12‑lead ECG (rEC…

Central Figure. Advanced Conduction Disease After Incident HF in Myotonic Dystrophy Type 1.

- Data from a pooled dose group of participants initially enrolled in the multiple ascending dose portion of the trial to be compared against a matched natural history cohort - - Dyne also intends to provide the mean baseline value for video hand opening time (vHOT) in the ACHIEVE registrational

This study shows that muscle stem cells fuse with existing muscle fibres in myotonic dystrophy type 1, producing centrally located nuclei with altered gene-expression states and reshaping diseased mus...

Myotonic dystrophy type 1 (DM1) is a progressive, multisystemic disorder in which gastrointestinal (GI) involvement is prevalent but frequently undere…

Subscription and open access journals from Sage, the world's leading independent academic publisher.

Subscription and open access journals from Sage, the world's leading independent academic publisher.

In this proof-of-concept study, 3D radiomic texture analysis of quantitative muscle MRI (proton density fat fraction (PDFF, %) maps) distinguished the myogenic disease DM1 from the neurogenic disease....

Background and ObjectivesAdult-onset myotonic dystrophy type 1 (DM1) is a progressive, multisystemic disorder, characterized by distal muscle weakness and myotonia. As disease-modifying therapies emer...

Piqueras-Losilla et al. show that the fatty-acid-conjugated antimiR-23b X82108 reaches the brain after systemic administration in mice and non-human primates. X82108 increases MBNL1/2 levels, reduces ...

Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are multisystemic diseases caused by the expression of toxic expansion RNAs that sequester muscleblind-like (MBNL) proteins, resulting in extensive alt...

Patients with myotonic dystrophy type 1 (DM1) are at increased risk of sudden cardiac death, and cardiac screening is recommended to identify patients who may benefit from cardiac pacing. We evaluated...

Introduction Myotonic dystrophy type 1 (DM1) is an autosomal dominant dynamic mutation disorder characterized by myotonia and muscle weakness. The genotype-phenotype relationship has not been clearly ...

New research suggests that myotonia—the delayed relaxation of muscles that causes stiffness—may be more than a symptom of myotonic dystrophy type 1. In animal models, eliminating myotonia improved mus...

Myotonia is a hallmark symptom of myotonic dystrophy (DM1). Eliminating myotonia in a DM1 mouse model improved muscle function and corrected transcriptome dysregulation, supporting myotonia as a drive...

Myotonic dystrophy type 1 (DM1) is a multisystemic autosomal dominant disorder caused by the expansion of an unstable CTG•CAG repeat in the DMPK gene.…

Subscription and open access journals from Sage, the world's leading independent academic publisher.

Myotonic dystrophy type 1 (DM1) is a dominant inherited autosomal disorder. It is the most common neuromuscular disorder in adults with the prevalence of 9-14/100,000 individuals worldwide [1,2] which...

Quercetin, a dietary flavonoid with emerging therapeutic relevance in myotonic dystrophy type 1 (DM1), has low solubility and poor oral bioavailability. Enzymatically modified isoquercitrin (EMIQ),...

GeneTAC® small molecule designed to selectively reduce transcription of the mutant DMPK allele and address the underlying cause of DM1 CARLSBAD, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Design Therap...

An expanded CTG repeat in the Dystrophia Myotonica Protein Kinase (DMPK) gene is associated with myotonic dystrophy type 1 (DM1), an autosomal dominan…

Abstract. Oligonucleotides are a promising class of genetic medicine for myotonic dystrophy type 1 (DM1), the most common adult-onset muscular dystrophy. H

Myotonic dystrophy (DM) is a multisystemic disorder characterized by significant heterogeneity in symptom manifestation, progression, and severity. This variability complicates clinical trial design a...

Background Prominent symptoms in myotonic dystrophy (DM) negatively affect the hands/arms (DM1), legs (DM2), or relate to fatigue. Myotonia is experienced by 90% of people with DM1 and is generally th...

Myotonic dystrophies (DM) are autosomal dominant, multisystemic disorders characterized by myotonia and progressive muscle weakness. Extramuscular multisystem symptoms include involvement of the respi...

Background: Myotonic dystrophy type 1 (DM1) impacts women’s health in several ways, causing gynecological and obstetrical issues, among others. Documenting the ...

IntroductionMyotonic dystrophy type 1 (DM1) is a genetic disorder caused by CTG trinucleotide repeat expansion in the dystrophia myotonica-protein kinase (DM...

Myotonic dystrophy type 1 (DM1) is characterized by toxic RNA gain-of-function leading to cardiac conduction defects and life-threatening arrhythmias.…